Document is current
Any future updates will be listed below
-
Authors
Nakamura, Yoshihiro
Kurasawa, Shimon
Imaizumi, Takahiro
Hayashi, Terumasa
Narita, Ichiei
Tanabe, Kenichiro
Morita, Satoshi
Tsubakihara, Yoshiharu
Imai, Enyu
Akizawa, Tadao
Maruyama, Shoichi https://orcid.org/0000-0002-8858-632X
-
Funding
Funding for this research was provided by:
Translational Research Center for Medical Innovatio
Nagoya University
- License Information
-
More Information
Article History
Received: 13 November 2025
Accepted: 26 March 2026
First Online: 15 April 2026
Declarations
:
: IN has received speaker’s fees from AstraZeneca, Sanofi, Bayer, Kyowa Kirin and Otsuka Pharmaceutical, and research grants from Kyowa Kirin, Bayer, Terumo, Kaneko, Otsuka Pharmaceutical, Daiichi-Sankyo, Astellas Pharma, Sumitomo Pharma, Ono Pharmaceutical, and Amicus Therapeutics. S Morita has received honoraria from Kyowa Kirin and Chugai. EI has received honoraria from Kyowa Kirin, AstraZeneca, Ono Pharmaceutical and Daiichi-Sankyo, and research grants from Torii, Kyowa Kirin, Tanabe, Boehringer Ingelheim, and Daiichi-Sankyo. TA has received honoraria from Kyowa Kirin. S Maruyama has received honoraria for lectures.
: The protocol was approved by the institutional review board of each participating center and adhered to the principles of the Declaration of Helsinki, the Ethical Guidelines on Clinical Studies from Japan’s Ministry of Health, Labor, and Welfare (Tokyo, Japan), and the International Conference on Harmonization Good Clinical Practice guidelines.
: All participants in the study gave their written informed consent.
